Non-diabetic hyperglycaemia and cardiovascular risk: moving beyond categorisation to individual interpretation of absolute risk

[21] Lawes CM(2009)International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes Diabetes Care 32 1327-1334

[22] Bennett DA(2010)Diagnosis and classification of diabetes mellitus Diabetes Care 33 S62-S69

[23] Milne RJ(2004)Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study Am J Med 117 390-397

[24] Rodgers A(2002)Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 3143-3421

[25] Jackson R(2003)The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report Jama 289 2560-2572

[26] Khaw KT(2005)JBS 2: Joint British societies' guidelines on prevention of cardiovascular disease in clinical practice Heart 91 v1-v52

[27] Wareham N(2001)Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk) BMJ 322 15-18

[28] Bingham S(2010)Effect of nateglinide on the incidence of diabetes and cardiovascular events N Engl J Med 362 1463-1476

[29] Luben R(2009)Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Circulation 119 351-357

[30] Welch A(1991)Cardiovascular disease risk profiles Am Heart J 121 293-298

[21] Lawes CM(2009)International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes Diabetes Care 32 1327-1334

[22] Bennett DA(2010)Diagnosis and classification of diabetes mellitus Diabetes Care 33 S62-S69

[23] Milne RJ(2004)Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study Am J Med 117 390-397

[24] Rodgers A(2002)Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 3143-3421

[25] Jackson R(2003)The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report Jama 289 2560-2572

[26] Khaw KT(2005)JBS 2: Joint British societies' guidelines on prevention of cardiovascular disease in clinical practice Heart 91 v1-v52

[27] Wareham N(2001)Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk) BMJ 322 15-18

[28] Bingham S(2010)Effect of nateglinide on the incidence of diabetes and cardiovascular events N Engl J Med 362 1463-1476

[29] Luben R(2009)Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Circulation 119 351-357

[30] Welch A(1991)Cardiovascular disease risk profiles Am Heart J 121 293-298